eSight eyewear is the Star Trek like device that allows legally blind 13-year-old, Ethan LaCroix, the ability to play basketball with the Harlem Globetrotters
uniQure, the first and only company to have a gene therapy approved, will not seek to renew its gene therapy approval in Europe.
Dwight Koeberl, MD at Duke University talks about the latest studies being done to test gene therapy for Pompe disease.
The interview took place during Duke University's Pompe disease Patient Meeting held April 8th, 2017.
Juli Bollinger, M.S., genetic counsellor and researcher at John Hopkins University talks about the genetics of Huntington's disease and the data she presented at the Annual ACMG Clinical Genetics Meeting in Phoenix, AZ.
less than 1 week after announcing Dr Meeker will be leaving as the head of Genzyme, Rhythm Pharmaceutics announced he will be chairman of the board of directors for that company.
Juli Bollinger, M.S., at John Hopkins University talks about data she presented at the Annual ACMG Clinical Genetics Meeting showing that the majority of patients who tested for Huntington's disease prior to being symptomatic did think that testing for this rare, devastating disease was a good idea.
Gelbman believes that FDNA and Face2Gene are intently focused on making significant contributions to the rare disease field and believes that their technology will play an important part in realizing the full potential of precision medicine initiatives.
Doron Behar, MD, chief scientific officer at Gene By Gene talks about the company's new testing program for carrier or preconception genetic screening.
A study published in in the Journal of Clinical Investigation revealed that gene therapy cured 9 of 10 children with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID, aka Bubble Baby Disease).
Doron Behar, MD, chief scientific officer at Gene By Gene talks about the genomic revolution.